HOPE 3

The HOPE3 investigators published the results of the randomized clinical trial of blood pressure lowering (candesartan-hydrochlorothiazide), cholesterol lowering (with rosuvastatin) or both in patients with intermediate risk but no cardiovascular disease. The combined treatment and the cholesterol lowering therapy were associated with reduction in the primary end-point and component adverse cardiovascular events. Blood pressure alone was not associate with reduction in cardiovascular events. Subgroup analysis suggested there may be a beneficial effect in patients with baseline hypertension.

 

Blood Pressure Lowering and Cholesterol Lowering

 

 

Blood Pressure Lowering 

Cholesterol Lowering

Advertisements